

**CORRECTION TO “CHARACTERIZATION OF DASATINIB
AND ITS STRUCTURAL ANALOGS AS CYP3A4
MECHANISM-BASED INACTIVATORS AND THE PROPOSED
BIOACTIVATION PATHWAYS”**

In the article referenced above [Li X, He Y, Ruiz CH, Koenig M, and Cameron MD (2009) *Drug Metab Dispos* 37:1242–1250], for contributions to the chemistry required to synthesize analogs of dasatinib, Tomas Vojkovsky should be considered a co-author.

The authors regret this error and apologize for any inconvenience or confusion it may have caused.